We are live on ! Find out more

DCOY

Decoy Therapeutics

DCOY

Market cap $1.95M

2.97 USD

-0.04

1.33%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

2.96

-0.01

0.34%

1 day

-1.33%

5 days

-10%

1 month

-20.59%

3 months

-63.11%

6 months

-63.65%

Year to date

-62.02%

1 year

-95.84%

5 years

-99.99%

10 years

-100%

About: Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Employees: 11

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30%

Neutral 70%

Negative 0%

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute.

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier, MBA, LL.B.

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing

Decoy Therapeutics Inc. (NASDAQ:DCOY) shares are trading higher. The company announced a $21 million private placement financing with a healthcare investor at $5.91 per share.

Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the "PIPE"), which is expected to provide approximately $3.5 million in gross proceeds at closing, before deducting placement agent's fees and other financing expenses payable by the Company. The Company intends to use the net proceeds to advance its lead asset into clinical trials.

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London.

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B.

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Proactive Investors

hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker

hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically significant for the AIM-listed contract research organisation. The agreement covers a wide range of services to support Decoy's development of its Designable Multi-Antiviral candidates, a novel antiviral category targeting shared mechanisms across multiple respiratory viruses with a single, adaptable therapeutic approach.

hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker

Proactive Investors

hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics

hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has signed a consultancy contract with Decoy Therapeutics to support the development of a novel class of broad-spectrum respiratory antivirals. The engagement covers translational modelling, regulatory strategy, chemistry, manufacturing and controls consulting, non-clinical development support, and preparation of clinical and regulatory documentation for submissions to European and UK regulators, including the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.

hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic CAMBRIDGE, Mass., June 1, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement of the company's Designable Multi-Antiviral (D-MAV) candidates into Phase 1 first-in-human and Phase 2a human proof-of-concept studies.

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

See News Rankings

Price charts implemented using Lightweight Charts™